224 related articles for article (PubMed ID: 36056935)
1. IL4I1 enhances PD-L1 expression through JAK/STAT signaling pathway in lung adenocarcinoma.
Zhu J; Li Y; Lv X
Immunogenetics; 2023 Feb; 75(1):17-25. PubMed ID: 36056935
[TBL] [Abstract][Full Text] [Related]
2. MiR-30a-3p Suppresses the Growth and Development of Lung Adenocarcinoma Cells Through Modulating GOLM1/JAK-STAT Signaling.
Ding D; Zhang Y; Zhang X; Shi K; Shang W; Ying J; Wang L; Chen Z; Hong H
Mol Biotechnol; 2022 Oct; 64(10):1143-1151. PubMed ID: 35438415
[TBL] [Abstract][Full Text] [Related]
3. Salidroside suppresses the multiple oncogenic activates and immune escape of lung adenocarcinoma through the circ_0009624-mediated PD-L1 pathway.
Jin G; Ma M; Yang C; Zhen L; Feng M
Thorac Cancer; 2023 Aug; 14(24):2493-2503. PubMed ID: 37423604
[TBL] [Abstract][Full Text] [Related]
4. FOXA1/UBE2T Inhibits CD8
Pu J; Zhang D; Wang B; Zhu P; Yang W; Wang K; Yang Z; Song Q
Front Biosci (Landmark Ed); 2024 Apr; 29(4):134. PubMed ID: 38682180
[TBL] [Abstract][Full Text] [Related]
5. PSMA5 contributes to progression of lung adenocarcinoma in association with the JAK/STAT pathway.
Lu F; Zhou J; Chen Q; Zhu J; Zheng X; Fang N; Qiao L
Carcinogenesis; 2022 Aug; 43(7):624-634. PubMed ID: 35605971
[TBL] [Abstract][Full Text] [Related]
6. Silencing of Perilipin 3 Inhibits Lung Adenocarcinoma Cell Immune Resistance by Regulating the Transcription of PD-L1 Through c-Myc.
Men X; Zhu W
Immunol Invest; 2023 Nov; 52(7):815-831. PubMed ID: 37578465
[TBL] [Abstract][Full Text] [Related]
7. Alpha5 nicotinic acetylcholine receptor mediated immune escape of lung adenocarcinoma via STAT3/Jab1-PD-L1 signalling.
Zhu P; Jin Z; Kang G; Jia Y; Liu D; Zhang Q; Guo F; Jia Y; Jiao Y; Li J; Sun H; Ma X
Cell Commun Signal; 2022 Aug; 20(1):121. PubMed ID: 35971127
[TBL] [Abstract][Full Text] [Related]
8. AIM2 fosters lung adenocarcinoma immune escape by modulating PD-L1 expression in tumor-associated macrophages via JAK/STAT3.
Ye H; Yu W; Li Y; Bao X; Ni Y; Chen X; Sun Y; Chen A; Zhou W; Li J
Hum Vaccin Immunother; 2023 Dec; 19(3):2269790. PubMed ID: 37877820
[TBL] [Abstract][Full Text] [Related]
9. SPIB Knockdown Inhibits the Immune Escape of Ovarian Cancer Cells by Reducing PD-L1 (CD274) Expression and Inactivating the JAK/STAT Pathway.
Gu W; Qi G; Chen L
Iran J Immunol; 2023 Sep; 20(3):335-347. PubMed ID: 37452634
[TBL] [Abstract][Full Text] [Related]
10. Serum exosomal miR-16-5p functions as a tumor inhibitor and a new biomarker for PD-L1 inhibitor-dependent immunotherapy in lung adenocarcinoma by regulating PD-L1 expression.
Chen HL; Luo YP; Lin MW; Peng XX; Liu ML; Wang YC; Li SJ; Yang DH; Yang ZX
Cancer Med; 2022 Jul; 11(13):2627-2643. PubMed ID: 35347894
[TBL] [Abstract][Full Text] [Related]
11. MAX transcriptionally enhances PD-L1 to inhibit CD8+ T cell-mediated killing of lung adenocarcinoma cells.
Huang D; Wang X; Qian Y; Wu J; Chen B; Zhang D; Dong F; Li Y
Cell Immunol; 2023 Apr; 386():104706. PubMed ID: 36931054
[TBL] [Abstract][Full Text] [Related]
12. Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation.
Puyalto A; Rodríguez-Remírez M; López I; Macaya I; Guruceaga E; Olmedo M; Vilalta-Lacarra A; Welch C; Sandiego S; Vicent S; Valencia K; Calvo A; Pio R; Raez LE; Rolfo C; Ajona D; Gil-Bazo I
Mol Cancer; 2024 Apr; 23(1):78. PubMed ID: 38643157
[TBL] [Abstract][Full Text] [Related]
13. Solamargine improves the therapeutic efficacy of anti-PD-L1 in lung adenocarcinoma by inhibiting STAT1 activation.
Liu Q; Xu M; Qiu M; Yu J; Wang Q; Zhou Y; Lin Q; Cai X; Yang L; Zhao H; Zhao C; Xie X
Phytomedicine; 2024 Jun; 128():155538. PubMed ID: 38552432
[TBL] [Abstract][Full Text] [Related]
14. KIAA1429 Induces m6A Modification of LINC01106 to Enhance the Malignancy of Lung Adenocarcinoma Cells via the JAK/STAT3 Pathway.
Xu D; Wang Z; Li F
Crit Rev Immunol; 2024; 44(6):49-61. PubMed ID: 38848293
[TBL] [Abstract][Full Text] [Related]
15. PYCR1 knockdown inhibits the proliferation, migration, and invasion by affecting JAK/STAT signaling pathway in lung adenocarcinoma.
Gao Y; Luo L; Xie Y; Zhao Y; Yao J; Liu X
Mol Carcinog; 2020 May; 59(5):503-511. PubMed ID: 32133692
[TBL] [Abstract][Full Text] [Related]
16. MTHFD2 promotes PD-L1 expression via activation of the JAK/STAT signalling pathway in bladder cancer.
Li L; Zhang Y; Hu W; Zou F; Ning J; Rao T; Ruan Y; Yu W; Cheng F
J Cell Mol Med; 2023 Oct; 27(19):2922-2936. PubMed ID: 37480214
[TBL] [Abstract][Full Text] [Related]
17. Preclinical development and clinical studies of targeted JAK/STAT combined Anti-PD-1/PD-L1 therapy.
Chen M; Wang S
Int Immunopharmacol; 2024 Mar; 130():111717. PubMed ID: 38387193
[TBL] [Abstract][Full Text] [Related]
18. Transcription Factor ETV4 Activates AURKA to Promote PD-L1 Expression and Mediate Immune Escape in Lung Adenocarcinoma.
Yang P; He S; Ye L; Weng H
Int Arch Allergy Immunol; 2024 May; ():1-11. PubMed ID: 38781935
[TBL] [Abstract][Full Text] [Related]
19. Integrated analyzes identify CCT3 as a modulator to shape immunosuppressive tumor microenvironment in lung adenocarcinoma.
Huang J; Hu B; Yang Y; Liu H; Fan X; Zhou J; Chen L
BMC Cancer; 2023 Mar; 23(1):241. PubMed ID: 36918801
[TBL] [Abstract][Full Text] [Related]
20. FAM83A drives PD-L1 expression via ERK signaling and FAM83A/PD-L1 co-expression correlates with poor prognosis in lung adenocarcinoma.
Zhou F; Wang X; Liu F; Meng Q; Yu Y
Int J Clin Oncol; 2020 Sep; 25(9):1612-1623. PubMed ID: 32430734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]